Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities (2012-2017)
Scope of the Report
The report titled ‘Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17)’ provides an in depth analysis of IBS market on a global level. The report presents the global market sizing of IBS and also predicts the future growth of the market. The report also analyzes the various sub segments of the market and the worldwide sales of drugs available for the specific segment. Besides presenting the competitive landscape, the report also assesses the growth of IBS market in United States, Japan, and the United Kingdom. It also includes the penetration rate of the disorder in Germany, France, Italy, Spain and Belgium. In addition, the report focuses on the various growth drivers and challenges faced by the Irritable Bowel Syndrome (IBS) market.
Geographical Coverage
Irritable Bowel Syndrome or IBS is a gastrointestinal disorder in which the colon muscle contracts more readily. The high prevalence of this syndrome could be estimated from the fact that 1 out of every 5 American is affected by the disorder and it is more common in women. Though the exact cause of the disorder is still unknown, factors like food, medicine, lifestyle and emotional stress can trigger the condition.
The global IBS market holds immense business opportunities as there are very few drugs and treatment available in the market. Moreover, only about 60% of the patient suffering from the syndrome tends to seek medical aid. The market is characterized with high unmet demand for proper treatment and this has resulted in many ongoing research and clinical trials. At present Amitiza and Lotronex are the only FDA approved drugs available in the market, which has created a necessity for more drugs and therapies in the Irritable Bowel Syndrome market. The IBS market is likely to witness arrival of many other drugs and first class therapies in the foreseeable future leading to generic competition in the market.
The report titled ‘Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17)’ provides an in depth analysis of IBS market on a global level. The report presents the global market sizing of IBS and also predicts the future growth of the market. The report also analyzes the various sub segments of the market and the worldwide sales of drugs available for the specific segment. Besides presenting the competitive landscape, the report also assesses the growth of IBS market in United States, Japan, and the United Kingdom. It also includes the penetration rate of the disorder in Germany, France, Italy, Spain and Belgium. In addition, the report focuses on the various growth drivers and challenges faced by the Irritable Bowel Syndrome (IBS) market.
Geographical Coverage
- United States
- Market Size
- Laxatives market growth projections
- European Union
- Market Size
- Country wise Analysis
- Japan
- Market Size
- Prevalence based on Subtype
- Abbott Laboratories
- Lexicon Pharmaceuticals
- Ironwood
- Salix Pharmaceuticals
- Sucampo
Irritable Bowel Syndrome or IBS is a gastrointestinal disorder in which the colon muscle contracts more readily. The high prevalence of this syndrome could be estimated from the fact that 1 out of every 5 American is affected by the disorder and it is more common in women. Though the exact cause of the disorder is still unknown, factors like food, medicine, lifestyle and emotional stress can trigger the condition.
The global IBS market holds immense business opportunities as there are very few drugs and treatment available in the market. Moreover, only about 60% of the patient suffering from the syndrome tends to seek medical aid. The market is characterized with high unmet demand for proper treatment and this has resulted in many ongoing research and clinical trials. At present Amitiza and Lotronex are the only FDA approved drugs available in the market, which has created a necessity for more drugs and therapies in the Irritable Bowel Syndrome market. The IBS market is likely to witness arrival of many other drugs and first class therapies in the foreseeable future leading to generic competition in the market.
1. EXECUTIVE SUMMARY
2. GLOBAL IRRITABLE BOWEL SYNDROME (IBS) MARKET: AN ANALYSIS
2.1. IBS Market – Sizing and Growth (Actual and Forecast, by value)
2.2. IBS Market: Segment Analysis
2.2.1. IBS-D (Worldwide Sales and Competitive Landscape)
2.2.2. IBS-C (Worldwide Sales and Competitive Landscape)
3. GLOBAL IRRITABLE BOWEL SYNDROME (IBS) MARKET: GEOGRAPHICAL ANALYSIS
3.1. United States
3.1.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.1.2. U.S. laxative market growth projections (Actual and Forecast, by value)
3.2. Japan
3.2.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.2.2. Prevalence Based on Subtype (Gender and Age)
3.3. European Union
3.3.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.3.2. Country-wise Analysis (Based on Penetration rate)
4. PORTER’S FIVE FORCES ANALYSIS
5. GROWTH DRIVERS
6. CHALLENGES
7. COMPANY ANALYSIS
7.1. Abbott Laboratories
7.1.1. Business Description
7.1.2. Business Strategies
7.2. Lexicon Pharmaceuticals
7.2.1. Business Description
7.2.2. Business Strategies
7.3. Ironwood
7.3.1. Business Description
7.3.2. Business Strategies
7.4. Salix Pharmaceuticals
7.4.1. Business Description
7.4.2. Business Strategies
7.5. Sucampo
7.5.1. Business Description
7.5.2. Business Strategies
8. ABOUT US
2. GLOBAL IRRITABLE BOWEL SYNDROME (IBS) MARKET: AN ANALYSIS
2.1. IBS Market – Sizing and Growth (Actual and Forecast, by value)
2.2. IBS Market: Segment Analysis
2.2.1. IBS-D (Worldwide Sales and Competitive Landscape)
2.2.2. IBS-C (Worldwide Sales and Competitive Landscape)
3. GLOBAL IRRITABLE BOWEL SYNDROME (IBS) MARKET: GEOGRAPHICAL ANALYSIS
3.1. United States
3.1.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.1.2. U.S. laxative market growth projections (Actual and Forecast, by value)
3.2. Japan
3.2.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.2.2. Prevalence Based on Subtype (Gender and Age)
3.3. European Union
3.3.1. IBS Market – Sizing and Growth (Actual and Forecast, by No. of Patients)
3.3.2. Country-wise Analysis (Based on Penetration rate)
4. PORTER’S FIVE FORCES ANALYSIS
5. GROWTH DRIVERS
6. CHALLENGES
7. COMPANY ANALYSIS
7.1. Abbott Laboratories
7.1.1. Business Description
7.1.2. Business Strategies
7.2. Lexicon Pharmaceuticals
7.2.1. Business Description
7.2.2. Business Strategies
7.3. Ironwood
7.3.1. Business Description
7.3.2. Business Strategies
7.4. Salix Pharmaceuticals
7.4.1. Business Description
7.4.2. Business Strategies
7.5. Sucampo
7.5.1. Business Description
7.5.2. Business Strategies
8. ABOUT US
LIST OF FIGURES
Figure 1: Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Value, 2006-11 (US$ Million)
Figure 2: Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Value, 2012-17 (US$ Million)
Figure 3: Worldwide Sales of Lotronex, 2010-12 (US$ Million)
Figure 4: Worldwide Sales of Amitiza, 2010-12 (US$ Million)
Figure 5: Total Bowel Disorder Prescription Pharmaceuticals Market: Market Segmentation, US, 2011
Figure 6: United States Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Adult Population, 2006-11 (Million)
Figure 7: United States Irritable Bowel Syndrome (IBS) Therapeutics Market Size Forecast, By Adult Population, 2012-17 (Million)
Figure 8: United States Laxative Market Size, 2006-11 (US$ Million)
Figure 9: United States Laxative Market Size, 2012-17 (US$ Million)
Figure 10: No. of IBS/CC Patients in Japan, 2006-11 (Million)
Figure 11: No. of IBS/CC Patients in Japan, 2006-11 (Million)
Figure 12: Prevalence of IBS in Japan, By Subtype and Gender, 2008 (percentage)
Figure 13: Prevalence of IBS in Japan, By Gender and Age - group, 2008 (Percentage)
Figure 14: Prevalence of IBS in Japan, By Gender and Age - group, 2008 (Percentage)
Figure 15: No. of IBS Patients in European Union, 2006-11 (Million)
Figure 16: No. of IBS Patients in European Union, 20012-17 (Million)
Figure 17: Penetration in the European Countries, 2010
Figure 18: Porters Five Force Analysis
Figure 1: Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Value, 2006-11 (US$ Million)
Figure 2: Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Value, 2012-17 (US$ Million)
Figure 3: Worldwide Sales of Lotronex, 2010-12 (US$ Million)
Figure 4: Worldwide Sales of Amitiza, 2010-12 (US$ Million)
Figure 5: Total Bowel Disorder Prescription Pharmaceuticals Market: Market Segmentation, US, 2011
Figure 6: United States Irritable Bowel Syndrome (IBS) Therapeutics Market Size, By Adult Population, 2006-11 (Million)
Figure 7: United States Irritable Bowel Syndrome (IBS) Therapeutics Market Size Forecast, By Adult Population, 2012-17 (Million)
Figure 8: United States Laxative Market Size, 2006-11 (US$ Million)
Figure 9: United States Laxative Market Size, 2012-17 (US$ Million)
Figure 10: No. of IBS/CC Patients in Japan, 2006-11 (Million)
Figure 11: No. of IBS/CC Patients in Japan, 2006-11 (Million)
Figure 12: Prevalence of IBS in Japan, By Subtype and Gender, 2008 (percentage)
Figure 13: Prevalence of IBS in Japan, By Gender and Age - group, 2008 (Percentage)
Figure 14: Prevalence of IBS in Japan, By Gender and Age - group, 2008 (Percentage)
Figure 15: No. of IBS Patients in European Union, 2006-11 (Million)
Figure 16: No. of IBS Patients in European Union, 20012-17 (Million)
Figure 17: Penetration in the European Countries, 2010
Figure 18: Porters Five Force Analysis
LIST OF TABLES
Table 1: Competitive Landscape for IBS-D
Table 2: Competitive Landscape for IBS-C
Table 1: Competitive Landscape for IBS-D
Table 2: Competitive Landscape for IBS-C
